Clinicopathologic Aspects of 1p/19q Loss and the Diagnosis of Oligodendroglioma

Author:

Aldape Kenneth1,Burger Peter C.1,Perry Arie1

Affiliation:

1. From the Department of Pathology and Brain Tumor Center, The University of Texas M. D. Anderson Cancer Center, Houston (Dr Aldape); Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Md (Dr Burger); and Department of Pathology, Division of Neuropathology, Washington University School of Medicine, St Louis, Mo (Dr Perry)

Abstract

Abstract Context.—Significant interobserver variability exists with respect to the diagnosis of oligodendroglial neoplasms, especially their distinction from astrocytoma and mixed oligoastrocytoma. Combined loss of the short arm of chromosome 1 and the long arm of chromosome 19 has been shown to be both relatively specific to oligodendroglioma and, when present, a marker of improved prognosis in patients with these tumors. In addition, 1p/19q loss has been shown to be a marker of “classic” oligodendroglial histology. These findings raise questions as to the role of 1p/19q testing in clinical practice, both as a prognostic marker and as a potential diagnostic marker among infiltrating glial neoplasms. Objective.—This review discusses the issues raised above and tries to clarify the current status of 1p/19q evaluation in the diagnosis of oligodendroglioma. Data Sources.—Sources for this review include recent literature as well as the experience of 3 practicing neuropathologists. Conclusions.—1p/19q status is an important marker in oligodendroglioma. Loss of 1p/19q is associated with classic oligodendroglioma histology as well as improved prognosis. The combined 1p/19q marker will continue to be a clinically useful marker of prognosis and could potentially be incorporated into diagnostic criteria in the future.

Publisher

Archives of Pathology and Laboratory Medicine

Subject

Medical Laboratory Technology,General Medicine,Pathology and Forensic Medicine

Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Central Nervous System (CNS) Tumors;Tata Memorial Centre Textbook of Oncology;2024

2. Molecular testing for gliomas;Diagnostic Molecular Pathology;2024

3. Signaling pathways in brain tumors and therapeutic interventions;Signal Transduction and Targeted Therapy;2023-01-04

4. Treatment Response and Prognosis Evaluation in High‐Grade Glioma: An Imaging Review Based on MRI;Journal of Magnetic Resonance Imaging;2022-02-07

5. Central Nervous System;Gattuso's Differential Diagnosis in Surgical Pathology;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3